Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Oncoinvent ASA (7BG) vs. Competitors

2 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:7BGOncoinvent ASAEUR 6.60EUR 41.77M-0.85215.79%―Unlock the DE:7BG analyst price target with TipRanks PremiumDE:7BGUnlock the DE:7BG top-analyst price target with TipRanks Premium
BRRGFOncoinvent ASA$0.03$45.83M-0.850.00%―Unlock the BRRGF analyst price target with TipRanks PremiumDE:7BG vs BRRGFUnlock the BRRGF top-analyst price target with TipRanks Premium
CLRBCellectar Biosciences$0.80$8.86M-0.22-71.74%Moderate BuyUnlock the CLRB analyst price target with TipRanks PremiumDE:7BG vs CLRBUnlock the CLRB top-analyst price target with TipRanks Premium
FENCFennec Pharmaceuticals$13.09$474.85M571.6266.96%Moderate BuyUnlock the FENC analyst price target with TipRanks PremiumDE:7BG vs FENCUnlock the FENC top-analyst price target with TipRanks Premium
GERNGeron$0.87$588.19M-12.42-20.91%Strong BuyUnlock the GERN analyst price target with TipRanks PremiumDE:7BG vs GERNUnlock the GERN top-analyst price target with TipRanks Premium
KZIAKazia Therapeutics$4.92$61.36M-0.01-34.22%Strong BuyUnlock the KZIA analyst price target with TipRanks PremiumDE:7BG vs KZIAUnlock the KZIA top-analyst price target with TipRanks Premium
SRNESorrento Therapeutics$0.00$165.38K0.00-94.05%―Unlock the SRNE analyst price target with TipRanks PremiumDE:7BG vs SRNEUnlock the SRNE top-analyst price target with TipRanks Premium

Performance Comparison

-200%0%200%400%600%800%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:7BGOncoinvent ASA6.605.08334.21%
BRRGFOncoinvent ASA0.030.000.00%
CLRBCellectar Biosciences0.80-2.10-72.52%
FENCFennec Pharmaceuticals13.095.3769.56%
GERNGeron0.87-0.29-25.00%
KZIAKazia Therapeutics4.92-3.53-41.78%
SRNESorrento Therapeutics―――
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts